Skip to main content
KOBAYASHI PHARMACEUTICAL CO.,LTD. logo

KOBAYASHI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4967 ISIN · JP3301100008 LEI · 529900WBSL04KD6TKP95 T Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country JP Japan
Listing T 4967

About KOBAYASHI PHARMACEUTICAL CO.,LTD.

https://www.kobayashi.co.jp/english/

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) submitted under Article 24-4-2 of the Financial Instruments and Exchange Act of Japan. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 108
2026-03-25 Japanese
有価証券報告書－第108期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business analysis, and corporate information for the fiscal year ending December 31, 2025. The document header explicitly identifies it as '有価証券報告書' (Securities Report) submitted under the Financial Instruments and Exchange Act. FY 2025
2026-03-25 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act of Japan. This is a mandatory regulatory filing that accompanies a semi-annual or quarterly report to confirm the accuracy of the financial statements. Since it is a specific regulatory filing required by law and does not fit into the categories of the report itself (IR) or a simple announcement (RPA), it is classified as a Regulatory Filing (RNS).
2025-08-08 Japanese
半期報告書－第108期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) for Kobayashi Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which are characteristic of an interim/quarterly financial report. It is not an announcement of a report, but the report itself. H1 2025
2025-08-08 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report) and explicitly states in Section 1 that it is being submitted because resolutions were passed at the "第107期定時株主総会" (107th Annual General Meeting) held on March 28, 2025. Section 2 details the resolutions, including the election of directors and a supplementary auditor, and provides the voting results (賛成, 反対, 棄権). This content directly relates to the outcomes and proceedings of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). Although it is a report of the results, the structure and context strongly align with the materials presented or summarized following an AGM.
2025-03-31 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) submitted under the Financial Instruments and Exchange Act of Japan. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 2024
2025-03-28 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.